ADAMTS 13 Activity (From UK) at Chughtai Lab

ADAMTS 13 Activity (From UK) at Chughtai Lab

The ADAMTS 13 Activity (From UK) test offered by Chughtai Lab is a highly specialized, state-of-the-art molecular and enzymatic assay used to measure the level and function of the ADAMTS13 enzyme in human plasma. ADAMTS13, which stands for “a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13,” is a critical zinc-containing metalloprotease enzyme synthesized primarily in the liver. Its primary physiological role is to cleave ultra-large von Willebrand factor (UL-vWF) multimers into smaller, less adhesive fragments. When this enzyme is deficient or inhibited, these ultra-large multimers accumulate in the bloodstream, leading to spontaneous platelet aggregation, microvascular thrombosis, and the life-threatening clinical syndrome known as Thrombotic Thrombocytopenic Purpura (TTP).

Because the ADAMTS13 activity assay requires highly specialized laboratory infrastructure, advanced analytical platforms, and rigorous quality control, Chughtai Lab facilitates this test as an international referral investigation. The patient's blood sample is collected under strict pre-analytical conditions at Chughtai Lab locations across Pakistan, processed immediately to preserve enzyme stability, and shipped under specialized cold-chain conditions to an accredited partner reference laboratory in the United Kingdom. This ensures that patients and clinicians in Pakistan receive diagnostic results that meet the highest international standards of accuracy and clinical reliability.

The clinical importance of the ADAMTS 13 Activity (From UK) test cannot be overstated. It serves as the gold-standard diagnostic tool for differentiating TTP from other forms of thrombotic microangiopathy (TMA), such as Hemolytic Uremic Syndrome (HUS), atypical HUS (aHUS), and disseminated intravascular coagulation (DIC). Rapid and accurate differentiation is vital because the treatment pathways for these conditions differ significantly. For instance, acute TTP is a medical emergency requiring immediate therapeutic plasma exchange (TPE) and immunosuppressive therapy, whereas other TMAs may require supportive care, anticomplement therapy, or alternative interventions.

Clinical Procedure: What to Expect

Patient Preparation

Proper patient preparation is essential to ensure the accuracy of the ADAMTS 13 Activity (From UK) test, as pre-analytical variables can significantly impact enzymatic activity measurements. Patients and referring physicians must observe the following guidelines:

• Timing of Sample Collection: The blood sample must ideally be drawn before the initiation of therapeutic plasma exchange (TPE) or plasma infusion. Transfused donor plasma contains active ADAMTS13 enzyme, which will falsely elevate the patient's measured activity levels and potentially mask a severe deficiency.
• Fasting Requirements: Routine fasting is generally not required for this test. However, patients are advised to avoid excessively fatty meals for 8 to 12 hours before the blood draw, as lipemic plasma can interfere with the optical and fluorometric detection systems used in the assay.
• Medication Review: Inform the healthcare provider of all medications, especially anticoagulants like heparin, warfarin, or direct oral anticoagulants (DOACs). While standard therapeutic anticoagulants do not typically interfere with the ADAMTS13 activity assay directly, documenting their use is crucial for comprehensive clinical correlation.
• Hydration: Adequate hydration is recommended prior to the procedure to facilitate easy venous access and ensure a smooth blood draw.

During the Procedure

The sample collection process is performed by highly trained phlebotomists at Chughtai Lab, adhering to strict clinical protocols to prevent sample activation or degradation:

• Venipuncture: A standard venipuncture is performed, typically using a vein in the antecubital fossa (inner elbow). The phlebotomist will apply a tourniquet briefly, cleanse the site with an antiseptic solution, and insert a sterile needle to draw blood.
• Tube Selection: The blood is collected into a light blue-top tube containing 3.2% sodium citrate as an anticoagulant. This specific anticoagulant is critical for preserving coagulation factors and enzymatic activity.
• Fill Volume: The tube must be filled precisely to the indicated fill line to maintain the correct 9:1 blood-to-anticoagulant ratio. Underfilled or overfilled tubes alter the citrate concentration, leading to inaccurate results, and will be rejected by the laboratory.
• Immediate Processing: Once drawn, the tube is gently inverted 3 to 4 times to mix the blood with the anticoagulant. It is then immediately transported to the laboratory processing area, where it undergoes double centrifugation at controlled temperatures to obtain platelet-poor plasma.
• Freezing and Shipping: The separated plasma is aliquoted into labeled polypropylene tubes and immediately frozen at -70°C or lower. The sample remains frozen throughout storage and international transit to the UK reference laboratory, ensuring that the delicate metalloprotease enzyme does not degrade.

When is an ADAMTS 13 Activity (From UK) Performed?

Suspected Thrombotic Thrombocytopenic Purpura (TTP)

Physicians request this test immediately when a patient presents with clinical signs suggestive of TTP. Historically characterized by a classic pentad—microangiopathic hemolytic anemia (MAHA), thrombocytopenia, neurological deficits, renal impairment, and fever—modern clinical practice recognizes that the presence of even just thrombocytopenia and MAHA without another clear cause is sufficient to suspect TTP and initiate testing.

Differentiating Thrombotic Microangiopathies (TMAs)

Thrombotic microangiopathies share overlapping clinical features, making diagnosis challenging. The ADAMTS 13 Activity test is performed to distinguish TTP from atypical Hemolytic Uremic Syndrome (aHUS), Shiga-toxin-producing Escherichia coli HUS (STEC-HUS), and secondary TMAs associated with autoimmune diseases, pregnancy (such as HELLP syndrome), or bone marrow transplantation. An activity level below 10% is highly specific for TTP, whereas other TMAs typically present with normal or mildly reduced activity.

Monitoring Therapeutic Plasma Exchange (TPE)

In patients diagnosed with TTP, the test is used to monitor the effectiveness of therapeutic plasma exchange. Tracking the recovery of ADAMTS13 activity levels helps clinicians assess treatment response, determine the appropriate timing for tapering plasma exchange, and identify patients who may be refractory to standard therapy and require adjunctive treatments like rituximab or caplacizumab.

Investigating Unexplained Thrombocytopenia and MAHA

When routine hematological evaluations reveal unexplained, profound thrombocytopenia accompanied by fragmented red blood cells (schistocytes) on a peripheral blood smear, the ADAMTS 13 Activity test is indicated. Identifying a severe deficiency early allows for life-saving interventions before widespread microvascular thrombosis leads to irreversible organ damage.

Assessing Congenital vs. Acquired ADAMTS13 Deficiency

The test is performed alongside inhibitor assays to determine the underlying cause of the deficiency. An acquired deficiency is typically caused by autoantibodies (inhibitors) neutralizing the enzyme, whereas congenital TTP (Upshaw-Schulman syndrome) is characterized by a persistent hereditary deficiency without detectable inhibitors. Distinguishing between these two forms is crucial for long-term management and genetic counseling.

What Does an ADAMTS 13 Activity (From UK) Detect?

The ADAMTS 13 Activity (From UK) test is highly sensitive and capable of detecting a wide range of clinical and physiological states related to microvascular coagulation. Specifically, the test detects and evaluates:

• Severe enzyme deficiency (typically defined as less than 10% activity), which is diagnostic of acute Thrombotic Thrombocytopenic Purpura (TTP).
• Moderate enzyme deficiency (ranging between 10% and 50% activity), which can be associated with systemic inflammatory conditions, advanced liver disease, severe sepsis, or pregnancy.
• Normal enzyme activity (greater than 50% up to 150%), which effectively rules out classic TTP as the primary cause of a patient's thrombotic microangiopathy.
• The presence of circulating anti-ADAMTS13 autoantibodies when reflex inhibitor testing is performed on deficient samples.
• Hereditary absence of the enzyme, pointing toward congenital TTP (Upshaw-Schulman syndrome).
• The recovery of enzyme levels following successful therapeutic plasma exchange (TPE).
• Early biochemical signs of clinical relapse in patients who are in clinical remission but show declining enzyme activity.
• The differentiation of TTP from atypical Hemolytic Uremic Syndrome (aHUS), where enzyme activity remains largely preserved.
• The impact of systemic autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), on metalloprotease levels.
• The baseline enzymatic status of a patient prior to initiating targeted immunosuppressive therapies.
• Subclinical enzyme deficiencies in family members of patients diagnosed with hereditary TTP.
• The efficacy of donor plasma in restoring functional metalloprotease levels during active treatment.
• The exclusion of TTP in patients presenting with isolated, severe acute kidney injury.
• The presence of transplant-associated thrombotic microangiopathy (TA-TMA) post-hematopoietic stem cell transplant.
• Fluctuations in enzyme levels during pregnancy, helping manage patients with a history of gestational TTP.
• The clinical severity of microvascular thrombosis by correlating enzyme levels with organ damage markers.
• Refractory states where enzyme activity fails to rise despite intensive plasma exchange therapy.
• The biochemical response to novel therapies like recombinant ADAMTS13 or anti-vWF nanobodies.
• The stability of clinical remission during long-term follow-up of TTP survivors.
• The presence of neutralizing vs. non-neutralizing antibodies when combined with advanced antibody profiling.

Turnaround Time and Report Access at Chughtai Lab

Because the ADAMTS 13 Activity (From UK) test is an international referral investigation, the turnaround time is reflective of the specialized logistics involved. Once the sample is collected and processed at Chughtai Lab, it is prepared for temperature-controlled international shipment. The typical turnaround time for this test is approximately 7 to 10 working days. Chughtai Lab utilizes advanced tracking systems to monitor the sample's journey from Pakistan to the accredited partner laboratory in the United Kingdom, ensuring that the cold chain remains unbroken and sample integrity is fully preserved.

Once the analysis is completed by the UK reference laboratory, the verified results are securely transmitted back to Chughtai Lab's centralized laboratory information system (LIS). Patients and their referring physicians can access the diagnostic report immediately upon release. Reports can be downloaded online via the official Chughtai Lab website, accessed through the Chughtai Lab mobile application, or received directly on WhatsApp. This seamless digital reporting system ensures that critical diagnostic data reaches healthcare providers without delay, facilitating prompt clinical decision-making.

ADAMTS 13 Activity (From UK) Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
ADAMTS13 Activity Level	50% to 150% activity	<10% (Severe deficiency, diagnostic of TTP); 10% to 50% (Moderate deficiency, seen in sepsis, liver disease, or pregnancy)
Inhibitor Autoantibodies	Negative (No autoantibodies detected)	Positive (Indicates acquired, autoimmune-mediated TTP)
Platelet Count	150,000 to 450,000 /µL	Severe thrombocytopenia (often <20,000 /µL in acute TTP due to consumption)
Schistocytes (Peripheral Smear)	Absent or rare (<0.5%)	Present (Significant numbers, indicating microangiopathic hemolytic anemia)
Lactate Dehydrogenase (LDH)	Normal range (typically 140-280 U/L)	Markedly elevated (indicates severe intravascular hemolysis and tissue ischemia)
Serum Creatinine	Normal range (0.6 to 1.2 mg/dL)	Normal to mildly/moderately elevated (severe elevation points more toward HUS)
Unconjugated Bilirubin	Normal range (0.2 to 0.8 mg/dL)	Elevated (due to ongoing intravascular hemolysis)
Haptoglobin	Normal range (30 to 200 mg/dL)	Severely decreased or undetectable (indicates active intravascular hemolysis)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient's symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for ADAMTS 13 Activity (From UK)?

• Experienced Healthcare Professionals: Chughtai Lab employs a team of highly qualified pathologists, hematologists, and laboratory technologists who oversee specialized testing and ensure clinical accuracy.
• Patient-Focused Care: The organization prioritizes patient comfort, safety, and convenience at every step of the diagnostic journey.
• Quality Diagnostic Services: Chughtai Lab adheres to stringent international quality control standards, ensuring reliable and reproducible test results.
• Seamless International Logistics: The lab has established secure, temperature-controlled transport protocols to safely ship specialized samples to accredited partner laboratories in the United Kingdom.
• Modern Diagnostic Approach: Utilizing advanced laboratory information systems and state-of-the-art pre-analytical processing equipment to minimize errors.
• Convenient Report Access: Patients can easily download their reports via the Chughtai Lab website, mobile app, or receive them directly on WhatsApp.
• Nationwide Network: With numerous collection centers across Pakistan, patients can access high-end diagnostic services close to home.
• Commitment to Accurate Diagnosis: Chughtai Lab is dedicated to providing timely and precise diagnostic insights that empower clinicians to make life-saving treatment decisions.